1
Jacques Thilly: Luer connector with rotationally engaging piercing luer. SmithKline Beecham Biologicals, Zoltan Kerekes, Stephen Venetianer, Charles M Kinzig, July 10, 2001: US06258078 (131 worldwide citation)

A luer connector which facilitates connection of a hypodermic syringe to the vial, comprising a luer connectable to a syringe and which extends to a sharpened end capable of being driven through a puncturable vial closure to thereby puncture the closure; a luer support, mountable on a vial, and whic ...


2
Pierre Hauser, Pierre Voet, Moncef Slaoui, Nathalie Marie Josephe Claude Garcon Johnson, Pierre Desmons: Vaccine compositions containing 3-0 deacylated monophosphoryl lipid A. SmithKline Beecham Biologicals, July 7, 1998: US05776468 (73 worldwide citation)

Novel vaccine compositions comprising small particles of 3-O-deacylated monophosphoryl lipid A are provided. In particular the particle size is below 120 nm. Such vaccine compositions have superior immunological properties.


3
Martin Friede, Nathalie Garcon, Catherine Marie Ghislaine Gerard, Philippe Hermand: Vaccines. SmithKline Beecham Biologicals, Jeffery A Sutton, Stephen Venetianer, Charles M Kinzig, April 8, 2003: US06544518 (64 worldwide citation)

The present invention relates to adjuvant compositions which are suitable to be used in vaccines. In particular, the adjuvant compositions of the present invention comprises a saponin and an immunostimulatory oligonucleotide, optionally with a carrier. Also provided by the present invention are vacc ...


4
Camille Locht, Yves Lobet: Vaccine. SmithKline Beecham Biologicals, Alissa M Eagle, William T King, Edward T Lentz, July 28, 1998: US05786189 (51 worldwide citation)

The Bordetella pertussis toxin is genetically modified to express a toxin protein which is deficient in target-cell receptor binding and is used in a vaccine for protection against whooping cough.


5
Patricia Marie Momin, Nathalie Marie Josephe Garcon: Vaccines. SmithKline Beecham Biologicals, Zoltan Kerekes, Stephen Venetianer, Charles M Kinzig, November 14, 2000: US06146632 (38 worldwide citation)

The present invention provides vaccine compositions comprising an oil-in-water emulsion optionally with 3 De-O-acylated monophosphoryl lipid A and QS21. The vaccines compositions are potent inducers of a range of immune responses.


6
Nathalie Garcon: Adjuvant systems and vaccines. SmithKline Beecham Biologicals, Michael M Conger, April 15, 2008: US07357936 (37 worldwide citation)

The present invention provides vaccine and adjuvant formulation comprising an immunostimulant and a metal salt. The immunostimulant is adsorbed onto a particle of metal salt and the resulting particle is essentially devoid of antigen.


7
John Paul Prieels, Nathalie Marie Josephe Claude Garcon Johnson, Moncef Slaoui, Pietro Pala: Vaccine composition containing adjuvants. SmithKline Beecham Biologicals, Zoltan Kerekes, Edward T Lentz, Stephen Venetianer, May 12, 1998: US05750110 (36 worldwide citation)

The present invention provides vaccine compositions comprising 3 De-O-acylated monophosphoryl lipid A and QS21. The vaccines compositions are potent inducers of CTL and .gamma. IFN responses.


8
Wilfried Dalemans, Marcelle Van Mechelen, Claudine Bruck, Martin Friede: Method to enhance an immune response of nucleic acid vaccination. SmithKline Beecham Biologicals, William R Marjarian, Stephen Venetianer, Charlie M Kinzig, December 31, 2002: US06500432 (31 worldwide citation)

This invention provides a method to enhance an immune response of nucleic acid vaccination by simultaneous administration of a polynucleotide and a polypeptide of interest.


9
Eric Jacobs, Apolonia Rutgers: Method for obtaining expression of mixed polypeptide particles in yeast. SmithKline Beecham Biologicals, Zoltan Kerekes, Stephen Venetianer, Charles M Kinzig, October 23, 2001: US06306625 (30 worldwide citation)

The present invention provides a method for obtaining expression of a mixed hepatitis B surface antigen particle, e.g., a particle of mixed polypeptide composition, in yeast. Also disclosed is a method for obtaining multimeric structures presenting two or more polypeptides by expression in yeast as ...


10
Jean Petre, Pierre Hauser: Vaccine. Smithkline Beecham Biologicals, Zoltan Kerekes, Stephen Venetianer, Charles M Kinzig, January 11, 2000: US06013264 (25 worldwide citation)

Stable and effective multivalent vaccine compositions comprising Hepatitis B surface antigen (HBsAg) are described wherein the HBsAg component is stable for one week at 37.degree. C. and is highly immunogenic, for example when the vaccine is administered to infants. The compositions typically compri ...